BioXcel Therapeutics (BTAI) Net Income towards Common Stockholders (2017 - 2026)

BioXcel Therapeutics has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$14.3 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 27.84% year-over-year to -$14.3 million in Q2 2026; TTM through Jun 2026 was -$61.3 million, a 7.59% increase from a year earlier, with the FY2025 full-year figure at -$66.4 million, up 16.79% from the prior year.
• Net Income towards Common Stockholders was -$14.3 million for Q2 2026 at BioXcel Therapeutics, down from -$14.2 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$13.8 million in Q1 2025, with the low at -$54.3 million in Q4 2022.
• Average Net Income towards Common Stockholders over 5 years is -$28.9 million, with a median of -$21.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders sank 108.23% in 2022, then surged 63.42% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$54.3 million in 2022, then soared by 58.84% to -$22.4 million in 2023, then surged by 36.7% to -$14.2 million in 2024, then retreated by 1.41% to -$14.4 million in 2025, then advanced by 0.26% to -$14.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$14.3 million (Q2 2026), -$14.2 million (Q1 2026), and -$14.4 million (Q4 2025), per Business Quant data.